{"pmid":32473012,"title":"Response to Malkovsky.","text":["Response to Malkovsky.","J Infect Dis","Zeng, Qing-Lei","Ji, Fanpu","Zhang, Ji-Yuan","32473012"],"journal":"J Infect Dis","authors":["Zeng, Qing-Lei","Ji, Fanpu","Zhang, Ji-Yuan"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473012","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/infdis/jiaa313","keywords":["convalescent plasma therapy","coronavirus disease 2019 (covid-19)","mortality","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)","survival rate","viral shedding"],"weight":0,"_version_":1668255193481871361,"score":9.490897,"similar":[{"pmid":32348485,"pmcid":"PMC7197534","title":"Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients.","text":["Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients.","Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.","J Infect Dis","Zeng, Qing-Lei","Yu, Zu-Jiang","Gou, Jian-Jun","Li, Guang-Ming","Ma, Shu-Huan","Zhang, Guo-Fan","Xu, Jiang-Hai","Lin, Wan-Bao","Cui, Guang-Lin","Zhang, Min-Min","Li, Cheng","Wang, Ze-Shuai","Zhang, Zhi-Hao","Liu, Zhang-Suo","32348485"],"abstract":["Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier."],"journal":"J Infect Dis","authors":["Zeng, Qing-Lei","Yu, Zu-Jiang","Gou, Jian-Jun","Li, Guang-Ming","Ma, Shu-Huan","Zhang, Guo-Fan","Xu, Jiang-Hai","Lin, Wan-Bao","Cui, Guang-Lin","Zhang, Min-Min","Li, Cheng","Wang, Ze-Shuai","Zhang, Zhi-Hao","Liu, Zhang-Suo"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348485","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/infdis/jiaa228","keywords":["convalescent plasma therapy","coronavirus disease 2019 (covid-19)","fatality","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)","survival rate","viral shedding"],"topics":["Treatment"],"weight":1,"_version_":1666138494927372288,"score":95.60836}]}